|
Mental Health In The Medicare Part D Drug Benefit: A New Regulatory Model?
Julie Donohue
The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 represents the most significant expansion of Medicare benefits since the program’s inception and has important implications for mental health. Medicare will become a major payer for psychotropic medications through the new prescription drug benefit. The structure of the drug benefit’s delivery system creates incentives for plans to underprovide medications, like psychotropic drugs, that are used persistently and are associated with high expected costs. Regulators have put policies in place to counteract these incentives. This paper examines these strategies’ likely success and suggests additional approaches to be considered.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
J. M. Donohue, H. A. Huskamp, and S. H. Zuvekas
Dual Eligibles With Mental Disorders And Medicare Part D: How Are They Faring?
Health Aff.,
May 1, 2009;
28(3):
746 - 759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. West, J. E. Wilk, I. L. Muszynski, D. S. Rae, M. Rubio-Stipec, C. L. Alter, W. E. Narrow, and D. A. Regier
Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First 4 Months of the Medicare Prescription Drug Benefit
Am J Psychiatry,
May 1, 2007;
164(5):
789 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rosenberg
Overview of Medicare Part D prescription drug benefit: Potential implications for patients with psychotic disorders
Am. J. Health Syst. Pharm.,
January 15, 2007;
64(2_Supplement_1):
S18 - S23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
